Clinical Trials Browser

NCT04750954 2026-04-17

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Phase 1 Active not recruiting

29 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05249114 2026-04-13

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Phase 1 Active not recruiting

6 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05724108 2026-04-13

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Phase 2 Active not recruiting

94 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT04261855 2026-03-27

GoTHAM

Phase 1/2 Active not recruiting

19 enrolled

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT05142696 2026-03-17

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Phase 1/2 Active not recruiting

24 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer

NCT05109728 2026-03-16

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Phase 1 Active not recruiting

65 enrolled

CNS

Glioblastoma

NCT03971461 2026-03-11

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

Phase 2 Active not recruiting

32 enrolled

CNS

Meningioma

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 2 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT03972488 2026-01-21

NETTER-2

Phase 3 Active not recruiting

226 enrolled 14 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04234568 2025-12-22

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Phase 1 Active not recruiting

31 enrolled 16 charts

EndocrineNET

Neuroendocrine Tumors

NCT02743741 2025-12-03

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Phase NA Active not recruiting

195 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05459844 2025-09-05

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Phase 3 Active not recruiting

196 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT06398444 2025-09-05

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Phase 2/3 Active not recruiting

74 enrolled

Endocrine

Advanced Neuroendocrine Neoplasm

NCT03457948 2025-09-03

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Phase 2 Active not recruiting

32 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT04544098 2025-05-02

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

Phase EARLY_PHASE1 Active not recruiting

10 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05247905 2025-04-02

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 2 Active not recruiting

31 enrolled

Adenoma, Islet Cell

NCT02754297 2024-08-21

P-PRRT

Phase 2 Active not recruiting

275 enrolled

EndocrineNET

Carcinoid Tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors